Analytical Data
-
基因名
CD7
- Application
-
别名
GP40T-cell leukemia antigen;T-cell surface antigen Leu-9TP41; CD7
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P09564
-
表达区间
26-180aa
-
分子量
32.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD7 is a glycoprotein primarily expressed on the surface of T cells and some natural killer (NK) cells, playing a crucial role in the immune response and cell signaling. The study of CD7 has gained significant interest due to its involvement in various hematological malignancies, including T-cell leukemias and lymphomas. Understanding the molecular mechanisms and pathways involving CD7 can provide insights into tumor biology and potential therapeutic targets. Efforts to develop CD7 recombinant proteins have opened avenues for research into their functional roles in immunotherapy. By generating CD7 chimeric proteins or fusion constructs, scientists aim to elucidate the protein's interactions, signaling pathways, and its influence on immune cell activation. Furthermore, these recombinant proteins can serve as valuable tools in the development of CD7-targeted therapies, such as bispecific antibodies or CAR T-cell treatments, enhancing the specificity and effectiveness of treatments for CD7-positive malignancies. The study of CD7 recombinant proteins thus represents a promising frontier in immuno-oncology, paving the way for novel strategies to combat T-cell-related disorders.
